华东医药：全资子公司索米妥昔单抗注射液补充申请获批

Core Viewpoint - Huadong Medicine's subsidiary, Sino-American Huadong, received approval from NMPA for the conversion of the conditional approval of Somatuzumab injection to regular approval, applicable for specific ovarian cancer patients [1] Group 1: Product Approval - The product is an ADC innovative drug developed in collaboration with ImmunoGen, with Huadong Medicine holding exclusive rights in Greater China [1] - The approval was based on the results of a confirmatory Phase III clinical trial, and the product is already available in multiple locations [1] Group 2: Financial Performance - In the first three quarters of 2025, ELAHERE achieved sales revenue exceeding 45 million yuan, with global net revenue of 508 million USD [1] - The approval is expected to positively impact the company's future performance, although sales are influenced by various factors, leading to uncertainty [1]